Dr. Xiuyu Cai 蔡修宇
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer, nasopharyngeal cancer, gastrointestinal tumors (gastric, colorectal), hepatobiliary tumors, and breast cancer.
Dr. Cai is a Chief Physician with a doctorate in oncology and serves as a doctoral supervisor.
Professional roles
- Chair, Tumor Recurrence and Metastasis Committee, Guangzhou Anti-Cancer Association
- Chair, Immunotherapy Branch, Guangdong Health Care Association
- Vice Chair, Translational Medicine Professional Committee, Guangzhou Anti-Cancer Association
- Standing Committee Member, Young Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Cai Xiuyu). Papers usually list the name as Xiuyu Cai or Cai X.
Selected publications
97 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Med, 2026 (first author): Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial. PubMed 42026573
- Int J Surg, 2026 (senior author): Chimeric antigen receptor T-cell therapy in patients with lymphoma: a machine learning-driven decadal informatics network analysis. PubMed 41731893
- Int J Surg, 2025 (senior author): Large language model ChatGPT in healthcare scenarios: a global-scale, cross-sectional, machine learning-based informatics study. PubMed 41344376
- BMC Med, 2023 (senior author): The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial. PubMed 36927541
- Lung Cancer, 2022 (senior author): Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study. PubMed 35986977
- Transl Lung Cancer Res, 2021 (senior author): Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. PubMed 34430364
- Ann Transl Med, 2020 (first author): Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma. PubMed 33241025
- Transl Lung Cancer Res, 2020 (first author): New first-line treatment strategies for advanced lung squamous cell carcinoma. PubMed 32420085
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion